Vicebio has announced its aim to accelerate the development of novel vaccines against life-threatening respiratory viral infections using its novel molecular clamp technology platform. The technology has been developed by Professor Paul Young, Dr Daniel Watterson, Dr Keith Chappell and their respective groups at The University of Queensland (UQ) and licensed to Vicebio by UniQuest, the commercialisation company of UQ. Source: Pharmatimes 22/7/2022